Cyclacel Pharmaceuticals Inc CYCC:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 7:59 PM EDT
2.57quote price arrow up+0.27 (+11.74%)
Volume
223,021
Close
2.30quote price arrow up+0.51 (+28.49%)
Volume
327,921
52 week range
1.52 - 13.20
Loading...
  • Open1.86
  • Day High2.35
  • Day Low1.85
  • Prev Close1.79
  • 52 Week High13.20
  • 52 Week High Date07/19/23
  • 52 Week Low1.52
  • 52 Week Low Date04/16/24

Key Stats

  • Market Cap3.032M
  • Shares Out1.32M
  • 10 Day Average Volume0.04M
  • Dividend-
  • Dividend Yield-
  • Beta0.60
  • YTD % Change-13.86

KEY STATS

  • Open1.86
  • Day High2.35
  • Day Low1.85
  • Prev Close1.79
  • 52 Week High13.20
  • 52 Week High Date07/19/23
  • 52 Week Low1.52
  • 52 Week Low Date04/16/24
  • Market Cap3.032M
  • Shares Out1.32M
  • 10 Day Average Volume0.04M
  • Dividend-
  • Dividend Yield-
  • Beta0.60
  • YTD % Change-13.86

RATIOS/PROFITABILITY

  • EPS (TTM)-26.80
  • P/E (TTM)-0.09
  • Fwd P/E (NTM)-0.17
  • EBITDA (TTM)-25.422M
  • ROE (TTM)-216.30%
  • Revenue (TTM)419,999.987
  • Gross Margin (TTM)-
  • Net Margin (TTM)-5,370.24%
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date05/09/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Cyclacel Pharmaceuticals Inc

 

Profile

MORE
Cyclacel Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing cancer medicines based on cell cycle, transcriptional regulation and mitosis control biology. The transcriptional regulation program is evaluating fadraciclib, a Cyclin-dependent kinase 9 (CDK9) inhibitor, in solid tumors and hematological malignancies. The epigenetic/anti-mitotic program is evaluating plogosertib, in solid tumors and hematological malignancies....
Christopher Henney Ph.D.
Independent Chairman of the Board
Spiro Rombotis
President, Chief Executive Officer, Director
Paul Mcbarron
Chief Financial Officer, Chief Operating Officer, Executive Vice President - Finance, Secretary, Director
Address
200 Connell Dr Ste 1500
Berkeley Heights, NJ
07922-2811
United States

Top Peers

SYMBOLLASTCHG%CHG
RNVA
Rennova Health Inc
0.00-0.0001-99.00%
FWBI
First Wave BioPharma Inc
3.02-0.10-3.21%
BCEL
Atreca Inc
0.085+0.005+6.25%
APVO
Aptevo Therapeutics Inc
0.6826-0.0536-7.2806%
PHIO
Phio Pharmaceuticals Corp
0.671-0.029-4.1429%